BCAT2
Basic information
Region (hg38): 19:48795062-48811029
Previous symbols: [ "BCT2" ]
Links
Phenotypes
GenCC
Source:
- hypervalinemia and hyperleucine-isoleucinemia (Limited), mode of inheritance: AR
- hypervalinemia and hyperleucine-isoleucinemia (Strong), mode of inheritance: AR
- hypervalinemia and hyperleucine-isoleucinemia (Definitive), mode of inheritance: AR
- hypervalinemia and hyperleucine-isoleucinemia (Moderate), mode of inheritance: AR
Clinical Genomic Database
Source:
| Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
|---|---|---|---|---|---|
| Hypervalinemia and hyperleucine-isoleucinemia | AR | Biochemical | The condition can involve biochemical dysfunction leading to neurologic and other manifestations, and dietary and medical management (eg, with pharmacologic doses of B6 or branched-chain amino acid restricted diet ) have been reported as yielding clinical and biochemical benefits | Biochemical; Neurologic | 25653144; 31177572 |
ClinVar
This is a list of variants' phenotypes submitted to
- not_provided (106 variants)
- not_specified (44 variants)
- Hypervalinemia_and_hyperleucine-isoleucinemia (8 variants)
- BCAT2-related_disorder (2 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the BCAT2 gene is commonly pathogenic or not. These statistics are base on transcript: NM_000001190.4. Only rare variants are included in the table.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUSVUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 20 | 25 | ||||
| missense | 72 | 84 | ||||
| nonsense | 1 | |||||
| start loss | 0 | |||||
| frameshift | 3 | |||||
| splice donor/acceptor (+/-2bp) | 2 | |||||
| Total | 5 | 1 | 77 | 28 | 4 |
Highest pathogenic variant AF is 0.000048328573
GnomAD
Source:
| Gene | Type | Bio Type | Transcript | Coding Exons | Length |
|---|---|---|---|---|---|
| BCAT2 | protein_coding | protein_coding | ENST00000316273 | 11 | 15968 |
| pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
|---|---|---|---|---|---|---|
| 2.83e-12 | 0.144 | 125691 | 0 | 57 | 125748 | 0.000227 |
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
|---|---|---|---|---|---|---|
| Missense | 0.982 | 203 | 246 | 0.824 | 0.0000156 | 2503 |
| Missense in Polyphen | 74 | 94.003 | 0.78721 | 930 | ||
| Synonymous | 0.0928 | 104 | 105 | 0.988 | 0.00000692 | 798 |
| Loss of Function | 0.726 | 20 | 23.8 | 0.840 | 0.00000129 | 235 |
LoF frequencies by population
| Ethnicity | Sum of pLOFs | p |
|---|---|---|
| African & African-American | 0.000845 | 0.000844 |
| Ashkenazi Jewish | 0.00 | 0.00 |
| East Asian | 0.000332 | 0.000326 |
| Finnish | 0.000142 | 0.000139 |
| European (Non-Finnish) | 0.000239 | 0.000237 |
| Middle Eastern | 0.000332 | 0.000326 |
| South Asian | 0.0000653 | 0.0000653 |
| Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Catalyzes the first reaction in the catabolism of the essential branched chain amino acids leucine, isoleucine, and valine. May also function as a transporter of branched chain alpha-keto acids.;
- Pathway
- Pantothenate and CoA biosynthesis - Homo sapiens (human);Cysteine and methionine metabolism - Homo sapiens (human);Valine, leucine and isoleucine biosynthesis - Homo sapiens (human);Valine, leucine and isoleucine degradation - Homo sapiens (human);One carbon metabolism and related pathways;Branched-chain amino acid catabolism;Metabolism of amino acids and derivatives;leucine degradation;Metabolism;valine degradation;Valine, leucine and isoleucine degradation;isoleucine degradation;Valine Leucine Isoleucine degradation
(Consensus)
Recessive Scores
- pRec
- 0.180
Intolerance Scores
- loftool
- 0.926
- rvis_EVS
- 0.17
- rvis_percentile_EVS
- 65.96
Haploinsufficiency Scores
- pHI
- 0.180
- hipred
- N
- hipred_score
- 0.208
- ghis
- 0.537
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.991
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Bcat2
- Phenotype
- adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan); growth/size/body region phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); homeostasis/metabolism phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); renal/urinary system phenotype;
Gene ontology
- Biological process
- isoleucine catabolic process;branched-chain amino acid biosynthetic process;branched-chain amino acid catabolic process;leucine biosynthetic process;valine biosynthetic process;regulation of hormone levels;cellular response to leukemia inhibitory factor
- Cellular component
- mitochondrion;mitochondrial matrix
- Molecular function
- branched-chain-amino-acid transaminase activity;L-leucine transaminase activity;L-valine transaminase activity;L-isoleucine transaminase activity